Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glioblastoma renin-angiotensin system oral combination study
ACTRN12622001201763Phase 2Recruiting
- Sponsor
- Gillies McIndoe Research Institute
- Start
- Jul 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aliskiren, celecoxib, curcumin, metformin, propranolol and 1 more in glioblastoma (GBM), sponsored by Gillies McIndoe Research Institute. Primary endpoint: Overall median survival from diagnosis. Started Jul 2024; status: recruiting.
02
Drugs
aliskirencelecoxibcurcuminmetforminpropranolol
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ACTRN12622001201763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001201763.